Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
In pharmacology, an indirect agonist or indirect-acting agonist is a is a substance that enhances the release or action of an endogenous neurotransmitter but has no specific agonist activity at the neurotransmitter receptor itself. Indirect agonists work through varying mechanisms to achieve their effects, including transporter blockade, induction of transmitter release, and inhibition of transmitter breakdown.
Mechanisms of indirect agonismEdit
Cocaine is a monoamine transporter blocker and, thus, an indirect agonist of dopamine receptors. Cocaine binds the dopamine transporter (DAT), blocking the protein's ability to uptake dopamine from the synaptic cleft and terminating dopamine signaling. Blockage of DAT increases the extracellular concentration of dopamine, therefore increasing the amount of dopamine receptor binding and signaling.
Evoking transmitter releaseEdit
Fenfluramine is an indirect agonist of serotonin receptors. Fenfluramine binds to the serotonin transporter, blocking serotonin reuptake. However, fenfluramine also acts to induce non-exocytotic serotonin release; in a mechanism similar to that of methamphetamine in dopamine neurons, fenfluramine binds to VMAT2, disrupting the compartmentalization of serotonin into vesicles and increasing the concentration of cytoplasmic serotonin available for drug-induced release.
Inhibition of clearanceEdit
Dipyridamole inhibits reuptake of adenosine, resulting in greater extracellular concentrations of adenosine. Dipyridamole also inhibits the enzyme adenosine deaminase, the enzyme that catalyzes the breakdown of adenosine.
- ↑ Katz JL, Izenwasser S, Terry P (2000). Relationships among dopamine transporter affinities and cocaine-like discriminative-stimulus effects. Psychopharmacology (Berl.) 148 (1): 90–8.
- ↑ Wang YX, Bowersox SS, Pettus M, Gao D (1999). Antinociceptive properties of fenfluramine, a serotonin reuptake inhibitor, in a rat model of neuropathy. J. Pharmacol. Exp. Ther. 291 (3): 1008–16.
- ↑ Baumann MH, Ayestas MA, Dersch CM, Partilla JS, Rothman RB (2000). Serotonin transporters, serotonin release, and the mechanism of fenfluramine neurotoxicity. Ann. N. Y. Acad. Sci. 914: 172–86.
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|